Current Report Filing (8-k)
June 28 2017 - 6:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 26, 2017
EPIZYME, INC.
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-35945
|
|
26-1349956
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
400 Technology Square, Cambridge, Massachusetts
|
|
02139
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 229-5872
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Epizyme, Inc. (the Company) previously disclosed in its annual report on Form
10-K
for the fiscal year
ended December 31, 2016 that Robert Copeland, President of Research and Chief Scientific Officer, would be retiring from the Company on a date to be determined in the second quarter of 2017 to pursue advisory and other opportunities within the
industry. The Company and Dr. Copeland have determined that Dr. Copelands retirement will be effective June 30, 2017, and that Dr. Copeland will not provide ongoing advisory services to the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
EPIZYME, INC.
|
|
|
|
|
Date: June 28, 2017
|
|
|
|
By:
|
|
/s/ Andrew E. Singer
|
|
|
|
|
|
|
Andrew E. Singer
|
|
|
|
|
|
|
Executive Vice President, Finance and Accounting,
Chief Financial Officer and Treasurer
|
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Sep 2023 to Sep 2024